...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of hematology >Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: A case report
【24h】

Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: A case report

机译：来那度胺成功治疗硼替佐米治疗期间睾丸侵犯难治性多发性骨髓瘤1例

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A 64-year-old man was diagnosed with symptomatic multiple myeloma (MM) in June 2009. No extramedullary region including the testes was detected. Serum protein electrophoresis showed IgA-Kappa monoclonal protein. Durie-Salmon stage was IIIA and International Staging System stage was n. Treatment was initiated with pulsed dexamethasone and bortezomib (1.3 mg/m2) twice weekly with dexamethasone (20 mg on the day of bortezomib administration and the next day). Without any adverse events, he achieved very good partial response (VGPR) after three cycles of bortezomib therapy [1]. Subsequently, he received high-dose melphalan (200 mg/m2) followed by autolo-gous stem cell transplantation (ASCT) in November 2009. After ASCT, he was followed up without any therapeutic agents. However, in September 2010, he complained of hip pain, and serum IgA level was elevated to 2,014 mg/dl. As recurrence of MM was diagnosed, we started weekly bortezomib with dexamethasone. The patient soon experienced improvement of symptoms, and serum IgA decreased to normal levels.
机译：2009年6月，一名64岁男子被诊断为有症状的多发性骨髓瘤（MM）。未检测到包括睾丸在内的髓外区域。血清蛋白电泳显示IgA-κ单克隆蛋白。 Durie-Salmon阶段为IIIA，国际分期系统阶段为n。每周两次用地塞米松和硼替佐米（1.3 mg / m2）脉冲地塞米松（在服用硼替佐米的第二天和第二天给予20 mg）开始治疗。在没有任何不良事件的情况下，他在三个周期的硼替佐米治疗后达到了很好的部分反应（VGPR）[1]。随后，他接受了大剂量美法仑（200 mg / m2），随后于2009年11月进行了自体干细胞移植（ASCT）。ASCT之后，他没有进行任何治疗。然而，在2010年9月，他抱怨髋关节疼痛，血清IgA水平升高至2,014 mg / dl。由于诊断出MM复发，因此我们开始每周一次与地塞米松一起使用硼替佐米。患者很快出现症状改善，血清IgA降至正常水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号